

~~Insert the Sequence Listing as pages 58-68.~~

~~Renumber the Claims as pages 69-72.~~

~~Renumber the Abstract as page 73.~~

**In the Claims:**

1. (Amended) A cell containing a composition comprising:

a) an [exogeneous]exogenous scaffold having no enzymatic activity and comprising at least a first binding site and a second binding site; and  
b) at least a first and a second enzyme, wherein at least one of said enzymes is heterologous to said cell;  
wherein said first enzyme is bound to said first binding site and said second enzyme is bound to said second binding site.

2. (Amended) A cell containing a composition comprising:

a) nucleic acid encoding an [exogeneous]exogenous scaffold having no enzymatic activity and comprising at least a first binding site and a second binding site; and  
b) nucleic acid encoding at least a first and a second enzyme, wherein at least one of said enzymes is heterologous to said cell;  
wherein said first enzyme is capable of being bound to said first binding site and said second enzyme is capable of being bound to said second binding site.

8. (Amended) A cell according to claim 1 or 2, further comprising

c) an [exogeneous]exogenous bioactive agent precursor.

Please add the following new claims:

--27. A cell according to claim 1 or 2, wherein said cell is a mammalian cell.

28. A cell according to claim 1 or 2, wherein said scaffold is linear.

29. A cell according to claim 1 or 2, wherein said scaffold is circular.

30. A cell according to claim 1 or 2, wherein said scaffold is branched.

*510 33*  
31. A cell according to claim 1 or 2, wherein said scaffold further comprises a fusion partner.

*510 33*  
32. A cell according to claim 1 or 2, wherein at least one of said enzymes further comprises a fusion partner.

33. A cell according to claim 31, wherein said fusion partner is a presentation structure.

*510 34*  
34. A cell according to claim 31, wherein said fusion partner is a targeting sequence.

*510 34*  
35. A cell according to claim 31, wherein said fusion partner is a rescue sequence.

*510 34*  
36. A cell according to claim 31, wherein said fusion partner is a stability sequence.

*510 34*  
37. A cell according to claim 31, wherein said fusion partner is a linker sequence.

38. A cell according to claim 32, wherein said fusion partner is a presentation structure.

*510 39*  
39. A cell according to claim 32, wherein said fusion partner is a targeting sequence.

40. A cell according to claim 32 wherein said fusion partner is a rescue sequence.

41. A cell according to claim 32, wherein said fusion partner is a stability sequence.

42. A cell according to claim 32, wherein said fusion partner is a linker sequence.--

---

**REMARKS**

Claims 1-8 and 27 - 42 are pending. Claims 1-8 have been examined on their merits. An Appendix of the claims is attached for the Examiner's convenience. The amendments to the specification are to comply with sequence disclosure requirements